

Ankylosing Spondylitis Drugs Market 2026

<https://marketpublishers.com/r/A3343DA813A2EN.html>

Date: January 2026

Pages: 218

Price: US\$ 2,999.00 (Single User License)

ID: A3343DA813A2EN

Abstracts

The Ankylosing Spondylitis Drugs Market was valued at in and is anticipated to reach by , at a CAGR of xx% from 2026 to 2032.

The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Ankylosing Spondylitis Drugs Market.

This report delivers a comprehensive overview of the Ankylosing Spondylitis Drugs Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Ankylosing Spondylitis Drugs Market. The Ankylosing Spondylitis Drugs Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for –.

Ankylosing Spondylitis Drugs Market Scope:

By Drug Class

Tumor necrosis factor (TNF) blocker

Non-steroidal anti-inflammatory drugs

Disease-modifying antirheumatic drugs

Interleukin-17 (IL-17) inhibitor

Others

By Route of Administration

Parenteral

Oral

By Distribution Channel

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Others

Key Players

Novartis AG

Merck & Co., Inc

Regeneron Pharmaceuticals, Inc

Amgen Inc

AbbVie Inc

Eli Lilly and Company

UCB, S.A

Johnson & Johnson Services, Inc

Bristol-Myers Squibb Company

Pfizer Inc(LIST NOT EXHAUSTIVE)

Major Highlights

This report delivers a comprehensive overview of the Ankylosing Spondylitis Drugs Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Ankylosing Spondylitis Drugs Market. The Ankylosing Spondylitis Drugs Market size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for –.

This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

Regional Analysis:

North America (U.S., Canada, Mexico)

Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

South America (Colombia, Brazil, Argentina, Rest of South America)

Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Partner Identification

Increase Your Customer Base by 3X using our Partner Identification tool

Uncover strategic collaboration opportunities with DataM vetted partners aligned to your ecosystem.

Identify high potential M&A targets based on synergies, market positioning and growth trajectory.

Prioritize partners by strategic fit rather than general capability.

Why Choose DataM?

Data-Driven Insights: Dive into detailed analyses with granular insights such as pricing, market shares and value chain evaluations, enriched by interviews with industry leaders and disruptors.

Post-Purchase Support and Expert Analyst Consultations: As a valued client, gain direct access to our expert analysts for personalized advice and strategic guidance, tailored to your specific needs and challenges.

White Papers and Case Studies: Benefit quarterly from our in-depth studies related to your purchased titles, tailored to refine your operational and marketing strategies for maximum impact.

Annual Updates on Purchased Reports: As an existing customer, enjoy the privilege of annual updates to your reports, ensuring you stay abreast of the latest market insights and technological advancements. Terms and conditions apply.

Specialized Focus on Emerging Markets: DataM differentiates itself by delivering in-depth, specialized insights specifically for emerging markets, rather than offering generalized geographic overviews. This approach equips our clients with a nuanced understanding and actionable intelligence that are essential for navigating and succeeding in high-growth regions.

Value of DataM Reports: Our reports offer specialized insights tailored to the

latest trends and specific business inquiries. This personalized approach provides a deeper, strategic perspective, ensuring you receive the precise information necessary to make informed decisions. These insights complement and go beyond what is typically available in generic databases.

Target Audience 2026

Manufacturers/ Buyers

Industry Investors/Investment Bankers

Research Professionals

Emerging Companies

Contents

1. METHODOLOGY AND SCOPE

- 1.1. Research Methodology
- 1.2. Research Objective and Scope of the Report

2. MARKET DEFINITION AND OVERVIEW

3. EXECUTIVE SUMMARY

- 3.1. Market Snippet by Drug Class
- 3.2. Market Snippet by Route of Administration
- 3.3. Market Snippet by Distribution Channel
- 3.4. Market Snippet by Region

4. MARKET DYNAMICS

- 4.1. Market Impacting Factors
 - 4.1.1. Drivers
 - 4.1.1.1. Introduction of novel products and the entry of biosimilars coupled with the increasing prevalence of the disease
 - 4.1.2. Restraints:
 - 4.1.2.1. High cost of treatment
 - 4.1.3. Opportunity
 - 4.1.4. Impact Analysis

5. INDUSTRY ANALYSIS

- 5.1. Porter's Five Forces Analysis
- 5.2. Pipeline Analysis
- 5.3. Epidemiology
- 5.4. Supply Chain Analysis
- 5.5. Pricing Analysis
- 5.6. Regulatory Analysis
- 5.7. Unmet Needs

6. COVID-19 ANALYSIS

- 6.1. Analysis of Covid-19 on the Market
 - 6.1.1. Before COVID-19 Market Scenario
 - 6.1.2. Present COVID-19 Market Scenario
 - 6.1.3. After COVID-19 or Future Scenario
- 6.2. Pricing Dynamics Amid Covid-19
- 6.3. Demand-Supply Spectrum
- 6.4. Government Initiatives Related to the Market During Pandemic
- 6.5. Manufacturers Strategic Initiatives
- 6.6. Conclusion

7. BY DRUG CLASS

- 7.1. Introduction
 - 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
 - 7.1.2. Market Attractiveness Index, By Drug Class
- 7.2. Tumor necrosis factor (TNF) blocker*
 - 7.2.1. Introduction
 - 7.2.2. Market Size Analysis, US\$ Million, 2019-2028 and Y-o-Y Growth Analysis (%), 2020-2028
 - 7.2.3. Adalimumab (Humira)
 - 7.2.4. Certolizumab pegol (Cimzia)
 - 7.2.5. Etanercept (Enbrel)
 - 7.2.6. Golimumab (Simponi)
 - 7.2.7. Infliximab (Remicade)
- 7.3. Non-steroidal anti-inflammatory drugs
 - 7.3.1. Ibuprofen
 - 7.3.2. Naproxen
- 7.4. Disease-modifying antirheumatic drugs
 - 7.4.1. Methotrexate
- 7.5. Interleukin-17 (IL-17) inhibitor
 - 7.5.1. Secukinumab (Cosentyx)
 - 7.5.2. Ixekizumab (Taltz)
- 7.6. Others

8. BY ROUTE OF ADMINISTRATION

- 8.1. Introduction
 - 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration

8.1.2. Market Attractiveness Index, By Route of Administration

8.2. Parenteral*

8.2.1. Introduction

8.2.2. Market Size Analysis, US\$ Million, 2019-2028 and Y-o-Y Growth Analysis (%), 2020-2028

8.3. Oral

9. BY DISTRIBUTION CHANNEL

9.1. Introduction

9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

9.1.2. Market Attractiveness Index, By Distribution Channel

9.2. Hospital Pharmacies*

9.2.1. Introduction

9.2.2. Market Size Analysis, US\$ Million, 2019-2028 and Y-o-Y Growth Analysis (%), 2020-2028

9.3. Retail Pharmacies

9.4. Online Pharmacies

9.5. Others

10. BY REGION

10.1. Introduction

10.1.1. Market Size Analysis, US\$ Million, 2019-2028 and Y-o-Y Growth Analysis (%), 2020-2028, By Region

10.1.2. Market Attractiveness Index, By Region

10.2. North America

10.2.1. Introduction

10.2.2. Key Region-Specific Dynamics

10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class

10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration

10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

10.2.6.1. U.S.

10.2.6.2. Canada

10.2.6.3. Mexico

10.3. Europe

10.3.1. Introduction

- 10.3.2. Key Region-Specific Dynamics
- 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
- 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
- 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
- 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
 - 10.3.6.1. Germany
 - 10.3.6.2. U.K.
 - 10.3.6.3. France
 - 10.3.6.4. Italy
 - 10.3.6.5. Spain
 - 10.3.6.6. Rest of Europe
- 10.4. South America
 - 10.4.1. Introduction
 - 10.4.2. Key Region-Specific Dynamics
 - 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
 - 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
 - 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
 - 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
 - 10.4.6.1. Brazil
 - 10.4.6.2. Argentina
 - 10.4.6.3. Rest of South America
- 10.5. Asia Pacific
 - 10.5.1. Introduction
 - 10.5.2. Key Region-Specific Dynamics
 - 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
 - 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
 - 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
 - 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
 - 10.5.6.1. China
 - 10.5.6.2. India
 - 10.5.6.3. Japan
 - 10.5.6.4. Australia
 - 10.5.6.5. Rest of Asia Pacific
- 10.6. Middle East and Africa
 - 10.6.1. Introduction
 - 10.6.2. Key Region-Specific Dynamics

10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class

10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration

10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

11. COMPETITIVE LANDSCAPE

11.1. Key Developments and Strategies

11.2. Company Share Analysis

11.3. Product Benchmarking

11.4. Key Companies to Watch

11.5. Company with disruptive technology

11.6. Start-Up Companies

12. COMPANY PROFILES

12.1. Novartis AG*

12.1.1. Company Overview

12.1.2. Product Portfolio and Description

12.1.3. Key Highlights

12.1.4. Financial Overview

12.2. Merck & Co., Inc

12.3. Regeneron Pharmaceuticals, Inc

12.4. Amgen Inc

12.5. AbbVie Inc

12.6. Eli Lilly and Company

12.7. UCB, S.A

12.8. Johnson & Johnson Services, Inc

12.9. Bristol-Myers Squibb Company

12.10. Pfizer Inc(*LIST NOT EXHAUSTIVE)

13. DATAM INTELLIGENCE

13.1. Appendix

13.2. About Us and Services

13.3. Contact Us

I would like to order

Product name: Ankylosing Spondylitis Drugs Market 2026

Product link: <https://marketpublishers.com/r/A3343DA813A2EN.html>

Price: US\$ 2,999.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/A3343DA813A2EN.html>